Source-grounded facts extracted from Nautilus Biotechnology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Nautilus Biotechnology, Inc. shareholders approved Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation at the 2026-06-17 meeting.
“The vote to approve, on an advisory basis, the frequency of future Say on Pay Votes was as follows: 1-Year 2-Years 3-Years Abstentions 69,142,818 6,733 1,112,824 31,198”
Nautilus Biotechnology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-17 meeting.
“The vote to approve, on an advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025 (the “Say on Pay Vote”) was as follows: Votes For Votes Against Abstentions Broker Non-Votes 69,994,022 268,341 31,210 14,708,618”
Nautilus Biotechnology, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.
“The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions 84,937,704 27,748 36,739”
Nautilus Biotechnology, Inc. shareholders approved Election of Class II Directors at the 2026-06-17 meeting.
“The following nominees were elected to serve as Class II directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Parag Mallick 67,882,439 2,411,134 14,708,618 Farzad Nazem 67,994,844 2,298,729 14,708,618”
Nautilus Biotechnology, Inc. reported the quarter ended March 31, 2026 results: net income $14.7 million.
“Net loss was $14.7 million for the first quarter of 2026”
Nautilus Biotechnology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).
“rice of shares of the Company’s common stock for the 30 consecutive business day period between March 19, 2025, through April 30, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until October 28, 2025 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The letter has no immediate impact on the listing o”
Matthew McIlwain departed as Director at Nautilus Biotechnology, Inc..
“Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting”
Michael Altman departed as Director at Nautilus Biotechnology, Inc..
“each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors”
Vijay Pande departed as Director at Nautilus Biotechnology, Inc..
“each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors”
Michael Altman departed as Director at Nautilus Biotechnology, Inc..
“On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.”
Vijay Pande departed as Director at Nautilus Biotechnology, Inc..
“On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.”
Nautilus Biotechnology, Inc. reported the first quarter ended March 31, 2024 results: net income $18.7 million.
“Net loss was $18.7 million for the first quarter of 2024”
Nautilus Biotechnology, Inc. updated its Fiscal Year 2024 Outlook guidance (initiated).
“Fiscal Year 2024 Outlook • We expect full year operating expense to grow by approximately 25% relative to 2023 • We expect that cash and cash equivalents and investments of $264.1 million as of December 31, 2023 to provide a runway into the second half of 2026 • We expect to launch our platform, instruments, consumables, and software in 2025.”
Nautilus Biotechnology, Inc. reported the fiscal year ended December 31, 2023 results: net income $63.7 million.
“Net loss was $63.7 million for the year ended December 31, 2023”
Nautilus Biotechnology, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at $125,000,000 (effective 2024-02-28).
“On February 28, 2024, Nautilus Biotechnology, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having aggregate sales proceeds of up to $125,000,000”
Nautilus Biotechnology, Inc. reported the third quarter ended September 30, 2023 results: net income $15.9 million.
“Net loss was $15.9 million for the third quarter of 2023, as compared to a net loss of $14.1 million for the corresponding prior year period.”
Nautilus Biotechnology, Inc. reported second quarter ended June 30, 2023 results: net income $15.8 million.
“Net loss was $15.8 million for the second quarter of 2023”
Nautilus Biotechnology, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.
“The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: Votes For Votes Against Abstentions 108,805,235 299,293 111,677”
Nautilus Biotechnology, Inc. shareholders approved Election of Class II Directors at the 2023-06-14 meeting.
“The following nominees were elected to serve as Class II directors, each to hold office until the Company’s 2026 annual meeting of stockholders or until his respective successor has been duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Parag Mallick 94,833,268 717,809 13,665,128 Matthew McIlwain 92,148,474 3,402,603 13,665,128 Farzad Nazem 95,381,887 169,190 13,665,128”
Nautilus Biotechnology, Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $15.0 million.
“Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2023.”
Nautilus Biotechnology, Inc. reported the year-ended December 31, 2022 results: net income $57.9 million.
“Net loss was $57.9 million for the year-ended December 31, 2022”
Nautilus Biotechnology, Inc. reported third quarter ended September 30, 2022 results: net income $14.1 million.
“Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022.”
Nautilus Biotechnology, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting provisions, remove lock-up provisions, update board and officer provisions, and make conforming ministerial changes (effective 2022-10-27).
“On October 27, 2022, the Company’s board of directors, upon recommendation of the nominating and governance committee, amended and restated the Company’s amended and restated bylaws, effective immediately.”
Karen Akinsanya was appointed as Director at Nautilus Biotechnology, Inc..
“On March 30, 2022 , the board of directors (the “Board”) of Nautilus Biotechnology, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Karen Akinsanya to the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.